Description

GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-anti-virus–C48H70F3N11O15S—-[1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.|[2]Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37(3):798-806.—-1130.19–99.70–O=C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)[C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@@H](N)CCCCN)=O)=O)=O)CC(C=C2)=CC=C2O.OC(C(F)(F)F)=O–Infection–H2O : 1.82 mg/mL (ultrasonic;adjust pH to 4 with HCl)–Arenavirus—-Anti-infection–Peptides